Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 3/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 2/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL15880338 | 0.98 | MAPT (0.47) | MAPTNPSR1POLBL3MBTL1APP | |
| SCHEMBL30693943 | 0.86 | MAPT (0.36) | MAPTNPSR1POLBL3MBTL1CA1 | |
| SCHEMBL1000103 | 0.84 | MAPT (0.58) | MAPTNPSR1POLBL3MBTL1APP | |
| SCHEMBL22053026 | 0.79 | HSD17B10 (0.39) | MAPTPOLBL3MBTL1ALDH1A1GAA | |
| SCHEMBL935630 | 0.78 | TUBB1 (0.40) | MAPTNPSR1POLBL3MBTL1APP | |
| SCHEMBL29448365 | 0.78 | TUBB1 (0.40) | MAPTNPSR1POLBL3MBTL1APP | |
| SCHEMBL2498762 | 0.78 | MAPT (0.52) | MAPTNPSR1POLBL3MBTL1APP | |
| SCHEMBL31261040 | 0.78 | MAPT (0.42) | MAPTNPSR1POLBL3MBTL1EP300 | |
| SCHEMBL31211203 | 0.78 | MAPT (0.57) | MAPTNPSR1POLBL3MBTL1APP | |
| SCHEMBL13186794 | 0.78 | MAPT (0.42) | MAPTNPSR1POLBL3MBTL1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4644387-A2 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2025-05-15 | — | — | US | disclosed |
| CN-119912402-A | FTO inhibitor and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-05-02 | — | — | CN | disclosed |
| US-20250042917-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-12139496-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-4395892-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118302426-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-111936494-A | Substituted hydro-pyrido-azines as sodium channel inhibitors | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019191702-A1 | SUBSTITUTED HYDRO-PYRIDO-AZINES AS SODIUM CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-10-03 | — | — | WO | disclosed |
| US-20190300544-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| CN-105658642-A | Fibroblast growth factor receptor inhibitors | 蓝图药品公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-104540809-A | Inhibitors of fibroblast growth factor receptors | BLUEPRINT MEDICINES | 2015-04-22 | — | — | CN | disclosed |
| CN-102245609-A | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2011-11-16 | — | — | CN | disclosed |
| CN-102123991-A | 2-arylaminoquinazolines for the treatment of proliferative diseases | NOVARTIS AG | 2011-07-13 | — | — | CN | disclosed |
| WO-2011007091-A1 | DERIVATIVES OF 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS UROTENSIN-II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-20 | — | — | WO | disclosed |
| CN-101652352-A | Quinazolines for PDK1 inhibition | NOVARTIS VACCINES & DIAGNOSTIC | 2010-02-17 | — | — | CN | disclosed |
| CN-101454294-A | Quinazolines for pdk1 inhibition | NOVARTIS AG (CH) | 2009-06-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042917-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C3AR1 | MAPT 2968/4885NPSR1 104/4885POLB 4010/4885 |
| US-20190300544-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C3AR1 | MAPT 2968/4885NPSR1 104/4885POLB 4010/4885 |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | MAPT 4269/4885NPSR1 4702/4885POLB 70/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | MAPT 2352/4885NPSR1 4634/4885POLB 73/4885 |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | MAPT 3414/4885NPSR1 2006/4885POLB 289/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | MAPT 2371/4885NPSR1 4616/4885POLB 283/4885 |
| US-12139496-B2 | Therapeutic compounds and methods of use thereof | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C3AR1 | MAPT 2968/4885NPSR1 104/4885POLB 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.